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Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbid-
ity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, contributes to the high
vascular risk in individuals with DM. This prothrombotic milieu is due to increased platelet activity together with impaired fibrinolysis sec-
ondary to quantitative and qualitative changes in coagulation factors. However, management strategies to reduce thrombosis risk remain
largely similar in individuals with and without DM. The current review covers the latest in the field of antithrombotic management in DM.
The role of primary vascular prevention is discussed together with options for secondary prevention following an ischaemic event in dif-
ferent clinical scenarios including coronary, cerebrovascular, and peripheral artery diseases. Antiplatelet therapy combinations as well as
combination of antiplatelet and anticoagulant agents are examined in both the acute phase and long term, including management of individ-
uals with sinus rhythm and those with atrial fibrillation.
The difficulties in tailoring therapy according to the variable atherothrombotic risk in different individuals are emphasized, in addition to
the varying risk within an individual secondary to DM duration, presence of complications and predisposition to bleeding events. This re-
view provides the reader with an up-to-date guide for antithrombotic management of individuals with DM and highlights gaps in know-
ledge that represent areas for future research, aiming to improve clinical outcome in this high-risk population.
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Introduction
Despite advances in therapy, a diagnosis of diabetes mellitus (DM) is
associated with increased morbidity and reduced lifespan, mainly due
to vascular complications.1–3 Premature and more severe vascular
disease, as well as a prothrombotic environment, represent key
mechanisms for adverse vascular outcomes in this population.4 The
prothrombotic milieu develops secondary to increased platelet re-
activity coupled with hypofibrinolysis.5,6
Current treatment strategies to improve vascular outcomes in
individuals with DM are focused on revascularization of acute athero-
thrombotic occlusions, where possible, together with early introduc-
tion of antithrombotic therapies, usually by inhibiting platelet
function. This continues long-term coupled with multifactorial ther-
apy targeting hypertension, dyslipidaemia and dysglycaemia in order
to limit the progression of vascular pathology.
In this review, we discuss the latest in antithrombotic therapies for
the management of coronary artery disease (CAD), cerebrovascular
disease, and peripheral artery disease (PAD) in DM, covering thera-
pies for primary prevention, acute vascular occlusion and long-term
secondary prevention. Special emphasis is placed on the benefits and
risks of antithrombotic therapy combinations, with the overall aim of
providing the reader with an up-to-date guide for antithrombotic
management in DM. Search strategy is detailed in the Supplementary
material online, S1.
The thrombotic environment in
diabetes
Individuals with DM are prone to both arterial and venous throm-
bosis.7 DM is characterized by multiple pathological processes,
including hyperglycaemia, chronic inflammation, oxidative stress, and
associated metabolic conditions, that damage the endothelium and
increase platelet reactivity, resulting in a prothrombotic environment.
Endothelial dysfunction is a consistent finding in DM patients and con-
tributes to the prothrombotic shift (Figure 1).4
An array of mechanisms operate in platelets to enhance their re-
activity.8 Hyperglycaemia is associated with higher expression of
platelet receptors, including glycoprotein (GP) Iba, GPIIb/IIIa and
P2Y12,
9 reduced platelet membrane fluidity secondary to increased
glycation, higher thromboxane (TX) A2 synthesis together with
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increased platelet activation markers.10–12 Diabetes-associated oxi-
dative stress also increases production of F2-isoprostanes.13 TXA2
and F2-isoprostanes, in turn, activate the thromboxane receptors
and amplify platelet activation (Figure 1).14 Platelet hyper-reactivity
also results from diminished sensitivity to the inhibitory agents pros-
tacyclin, nitric oxide, and insulin,15–17 and from changes in platelet
content of miRNAs known to regulate platelet function (miR-223,
miR-26b, miR-126, miR-140).18,19 Moreover, the imbalance in intra-
platelet magnesium and calcium homeostasis renders platelets more
sensitive to epinephrine, adenosine diphosphate (ADP), and throm-
bin.20 DM is also characterized by accelerated platelet turnover, as
evidenced by release of more reactive, reticulated platelets21,22 that
display a reduced response to antiplatelet agents.23 Finally, platelets
from DM patients more easily externalize phosphatidylserine in the
outer platelet membrane, thereby providing a better surface for the
assembly of clotting factors and tissue factor activation.21,22
Other associated metabolic conditions like obesity, dyslipidaemia,
and systemic inflammation also contribute to thrombosis risk.6,24
Circulating inflammatory molecules [tumour necrosis factor-a,
interleukin (IL)-1 and IL-6, selectin, soluble CD40 ligand],17,25 besides
enhancing platelet reactivity, favour a hypercoagulable environment.
Furthermore, bone marrow transplants that created chimeras of nor-
mal rats with bone marrow cells from diabetic rats resulted in a pro-
thrombotic phenotype similar to the donor animals, indicating the
imprinting effects of DM on haematopoietic cells.22
Several prothrombotic alterations in the coagulation-fibrinolytic
system also occur in DM,26 including increased levels of tissue factor,
prothrombin, factor VII and fibrinogen coupled with impaired anti-
coagulant and fibrinolytic activity (Figure 1).27 Diabetic thrombi dis-
play compact fibrin networks with densely-packed thin fibres that are
resistant to fibrinolysis.6,26 Furthermore, hyperglycaemia induces
qualitative changes in plasminogen, hindering its fibrinolytic activity.28
Concomitantly, elevated levels of anti-fibrinolytic proteins (plasmino-
gen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibi-
tor),29 along with increased incorporation of anti-fibrinolytic proteins
(complement C3 and plasmin inhibitor) into the clot further com-
promise fibrinolysis.6 Despite this prothrombotic environment, DM
patients have a paradoxical increased risk of bleeding, particularly
Figure 1 Diabetes enhances the risk of thrombosis. Diabetes induces endothelial dysfunction with subsequent decline in the expression/release of
molecules that can reduce platelet activation and associated thrombus formation. At a platelet level, there are several mechanisms by which diabetes
could enhance platelet susceptibility to activation including: (i) a higher abundance of advanced glycation end-products (AGEs) which induces insulin
resistance and alters membrane fluidity; (ii) an enhanced oxidative stress which leads to the formation of isoprostanes which in turn induce platelet
activation by interacting with the thromboxane receptor (TP); (iii) a higher production of thromboxane (TXA2); and (iv) an increased expression of
multiple platelet activation receptors and a higher reactivity to several platelet agonists. As for coagulation, diabetes is associated with a higher
amount of tissue factor (TF), thrombin (factor II), and fibrinogen production, which, in concurrence with lower anticoagulant proteins [protein C-
antithrombin III complex (PC/ATIII)], favours the formation of the fibrin mesh, which undergoes glycation and oxidative modifications, becoming
more dense and resistant to fibrinolysis. Diabetes is also associated with a hypofibrinolytic state characterized by higher abundance of inhibitors of tis-
sue plasminogen activator (tPA) such as plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI), and increased
incorporation of antifibrinolytic proteins into the clot [plasmin inhibitor (PI) and complement 3 (C3)] which collectively reduce the efficiency of fibrin-
olysis. AA: arachidonic acid; ADP: adenosine diphosphate; Cox: cyclooxygenase; GP: glycoprotein; IRc: insulin receptors; miR: microRNAs; NO: nitric
oxide; PAR: protease-activated receptor; PGI2: prostacyclin; ROS: reactive oxygen species; TM: thrombomodulin; VLDL: very-low-density lipopro-
tein; vWF: vonWillebrand factor.



















































































































































































































































following an acute coronary syndrome (ACS).30 However, data on
stable patients are less clear: the dual antiplatelet therapy (DAPT)
study (detailed below under ‘Secondary Prevention’) reported no in-
crease in long-term moderate or severe bleeding events in those
with DM, possibly related to excluding those with bleeding events in
the first 12months, while increased risk was documented in the
REACH and CORONOR registries.31,32 The exact mechanisms for
the increase in both thrombosis and bleeding risk in some diabetes
patients are not fully understood, although renal complications may
have a role.33Also, chronic activation of platelet and coagulation pro-
teins may ‘exhaust’ the system in some DM patients, thus increasing
bleeding risk.34
Antithrombotic targets
For decades, the two main antithrombotic targets have been platelet
TXA2 production and platelet P2Y12 receptor activation.
Aspirin
Low-dose aspirin irreversibly inhibits platelet cyclooxygenase-1 en-
zyme, preventing the conversion of arachidonic acid into bioactive
prostanoid TXA2.
35 Given the short half-life of aspirin and increased
platelet turnover in DM, a proportion of platelets may escape 24-h
inhibition by once-daily aspirin, which can be re-established by twice-
daily dosing.23,36
P2Y12 receptor antagonists
ADP-stimulated effects on platelets are mediated primarily by Gi-
coupled P2Y12 receptor activation, leading to persistent platelet ag-
gregation, whereas P2Y1 is responsible for an initial weak, transient
phase of platelet aggregation.37 There are two main classes of orally
administered P2Y12 inhibitors: thienopyridines (ticlopidine, clopidog-
rel, and prasugrel) and non-thienopyridine agents (ticagrelor).38
Thienopyridines require conversion to an active metabolite that acts
irreversibly. Ticlopidine is no longer marketed in many countries due
to safety concerns.38 Ticagrelor is a direct-acting cyclopentyltriazolo-




Warfarin and other vitamin K antagonists (VKAs) require regu-
lar monitoring and this, together with high bleeding risk when
combined with antiplatelet therapy, prevented widespread
use.39 More modern approaches include modulation of throm-
bin activity either by blocking protease-activated receptor-1 on
platelet membrane (vorapaxar)40 or by directly inhibiting pro-
tein function (dabigatran).41 Other non-VKA oral anticoagu-
lants (NOAC) include inhibitors of activated factor Xa
(apixaban, rivaroxaban, and edoxaban).41 Supplementary ma-
terial online, Table S1 provides a summary of the main antith-
rombotic agents.
Antiplatelet therapy for primary
prevention of ischaemic events
Primary prevention is defined as offering therapy to individuals with-
out a history of a vascular ischaemic event. In the largest individual
data meta-analysis of primary prevention trials (n=95 000 individu-
als), aspirin use in DM was associated with a non-significant 12% rela-
tive risk reduction (RRR) of major adverse cardiac events (MACE),
from 1.87% to 1.63% per year [hazard ratio (HR) 0.88 (0.67–1.15);
Table 1].42 Although non-significant, this benefit was comparable to
non-DM individuals, in whom aspirin reduced yearly MACE from
0.57% to 0.51% [HR 0.88 (0.82–0.94); P=0.0001].42 Aspirin was
associated with an increase in extracranial, mainly gastrointestinal,
bleeding in both non-DM and DM populations (P=0.20 for hetero-
geneity; Table 1).42 Following this meta-analysis, the Japanese Primary
Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD)
(n=2539)43 and prevention of progression of arterial disease and dia-
betes (POPADAD) (n=1276)44 trials investigated aspirin in primary
prevention but, being small and underpowered, failed to provide con-
clusive data. The recent ASCEND trial is the largest, longest and only
adequately powered trial investigating primary prevention in DM,
randomizing 15 480 DM patients without symptomatic cardiovascu-
lar disease to aspirin (100mg daily) or placebo.45 Serious vascular
events occurred in 8.5% of individuals on aspirin vs. 9.6% on placebo
[RRR 12%, HR 0.88 (0.79–0.97); P=0.01]. Major bleeding, according
to the Bleeding Academic Research Consortium (BARC) 2, 3, and 5
categories,46 occurred in 4.1% and 3.2% in the aspirin and placebo
arms, respectively, without significant differences in fatal or intracra-
nial bleeding, although the absolute number of events was low
(Table 1).45 Notably, >50% of major bleeding excess with aspirin was
gastrointestinal. The number needed to treat (NNT)/number needed
to harm (NNH) ratio was 0.8, favouring treatment. Importantly,
BARC 2–5 bleeding criteria are less restrictive as compared to the
Thrombolysis in Myocardial Infarction (TIMI) major criteria.47–49 Of
note, there was no significant heterogeneity in the effect of aspirin
according to the estimated vascular risk at baseline. A meta-analysis
of 12 randomized controlled trials (RCTs) (34 227 individuals),
including the ASCEND population, showed that aspirin reduces
MACE by 11% compared with placebo [HR 0.89 (0.83–0.95)]
(Table 1).50
The THEMIS study tested intensification of antiplatelet regimen in
19 220 DM patients without previous myocardial infarction (MI) or
stroke but with evidence of clinical CAD and already on low-dose as-
pirin therapy (Table 1).47 Individuals randomized to aspirin and tica-
grelor had a modest reduction in vascular events compared with
aspirin alone [7.7% and 8.5%, respectively, HR 0.90 (0.81–0.99);
P=0.04], associated with a 2.3-fold increase in TIMI major bleeding
and a 1.7-fold increase in intracranial bleeding (Table 1), giving an un-
favourable NNT/NNH ratio of 1.48 and arguing against routine
DAPT with aspirin and ticagrelor in this population.
The recent European Society of Cardiology (ESC) guidelines indi-
cate that those with DM and >_1 organ damage or >_3 major risk fac-
tors, or any risk factor and >_10 years disease duration without organ
damage, should be considered for primary prevention, in the absence
of contraindications (Supplementary material online, Table S2) but
routine use of aspirin for all DM individuals is not recommended.51









































































Table 1 Primary prevention in diabetes
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POPADAD (2008)44 1276 adults aged
>_40 years with T1DM
or T2DM and ABI
<_0.99 (asymptomatic)
Death from CAD or
stroke, non-fatal MI or
stroke, or amputation
for critical limb ischae-
mia; and death from
CAD or stroke
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ASCEND (2018)45 15 480 Patients aged >_40
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Table 1 Continued























THEMIS (2019)47 19 220 patients with DM,
>_50 years, stable CAD
with no previous MI or
stroke
Randomized to ticagrelor
or placebo on a back-
ground of aspirin
therapy































Seidu et al. (2019)50











Summary of primary prevention studies.
Significant differences are reported in bold.
ABI, ankle-brachial index; BARC, Bleeding Academic Research Consortium; CAD, coronary artery disease; CV, cardiovascular; DM, diabetes mellitus; GI, gastrointestinal; HR, hazard ratio; ICH, intracranial haemorrhage; MI, myocardial in-
farction; NA, not applicable; NNH, number needed to harm; NNT, number needed to treat; PVD, peripheral vascular disease; RRR, relative risk reduction; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TIA, transient is-


























































































































































































Overall, guidelines recommend aspirin monotherapy for DM patients
with additional risk factor(s) and/or with an estimated annual risk of
vascular events >_1% (Supplementary material online, Table S2).52–54
Secondary prevention in the
absence of atrial tachyarrhythmias
Following acute coronary events
ACS guidelines recommend DAPT comprising aspirin and prasugrel
or ticagrelor, which applies to DM individuals.3,51,55,56 Patients with
DM, however, exhibit enhanced platelet reactivity and reduced sensi-
tivity to thienopyridines (but not ticagrelor),57,58 although the clinical
significance of these biochemical observations remains unclear.
Aspirin
Guidelines recommend routine early administration of aspirin in
ACS, which seems to offer similar benefits in individuals with and
without DM. Based on pharmacodynamic studies in DM,23,59,60 the
clinical benefit of twice-daily aspirin administration is being evaluated
in the ANDAMAN trial (NCT02520921). Higher aspirin doses (300–
325mg vs. 75–100mg) failed to reduce MACE 30days post-ACS in
the CURRENT-OASIS 7 study (23% had DM).61 The ongoing
ADAPTABLE study is assessing alternative aspirin dosing, although
this is not limited to the DM population.62Moreover, ongoing studies
are aiming to identify new low-dose aspirin formulations with poten-
tially improved safety and efficacy profiles.63,64
P2Y12 inhibitors
In individuals with DM, prasugrel or ticagrelor combination with as-
pirin is preferred to clopidogrel, which shows reduced effi-
cacy.30,56,65–67 Post hoc analysis of the DM population in the
TRITON-TIMI 38 trial showed marked benefit of prasugrel over clo-
pidogrel,66 while, in PLATO, the absolute benefit of ticagrelor over
clopidogrel was greatest in patients with both DM and chronic kidney
disease (CKD).68 In patients with ACS and insulin-requiring DM, tica-
grelor may achieve more potent platelet inhibition than prasugrel,57
although the clinical significance is unclear. The recent ISAR-REACT
5 study, an open-label trial, demonstrated superiority of a prasugrel-
based strategy over a ticagrelor-based strategy in reducing MACE in
ACS patients.69 However, this was not the case in the DM subgroup:
the composite primary endpoint (death, stroke, or MI) occurred in
11.2% and 13.0% in ticagrelor and prasugrel arms, respectively [HR
0.84 (0.58–1.24); P=0.383] with treatment interaction shown for
DM status (P=0.0035).70 Bleeding complications were similar in tica-
grelor- and prasugrel-treated DM individuals.
A difficulty with more potent oral P2Y12 inhibitors is the limited
evidence in the older population who are at higher bleeding risk.
Two smaller studies in ACS patients aged >_70 years, of whom a third
had DM, indicated that de-escalation from prasugrel or ticagrelor to
clopidogrel may be safe.71 Moreover, platelet-function-guided de-es-
calation from prasugrel to clopidogrel at hospital discharge may be
non-inferior to continued prasugrel but this strategy appears safer in
those without DM.72 The TWILIGHT study (n=7119) assessed
safety of de-escalating DAPT, from ticagrelor plus aspirin to ticagre-
lor monotherapy, after 3months of DAPT following high-risk
percutaneous coronary intervention (PCI) for ACS or chronic cor-
onary syndromes (CCS).73 Monotherapy reduced the primary end-
point of BARC type 2, 3, or 5 bleeding compared with DAPT at
12months [4.0% vs. 7.1%, HR 0.56 (0.45–0.68); P<0.001], similarly in
those with and without DM, without increasing the secondary com-
bined endpoint of death, MI, or stroke. More specifically, ticagrelor
monotherapy in the DM subgroup did not increase ischaemic events
compared with DAPT [4.6% vs. 5.9%; HR 0.77 (0.55–1.09); P=0.14]
but significantly decreased bleeding complications [4.5% vs. 6.7%; HR
0.65 (0.47–0.91); P=0.012].74 The GLOBAL LEADERS trial random-
ized individuals undergoing PCI with drug-eluting stents for CCS or
ACS to standard care (DAPT for 12months followed by aspirin
alone) or ticagrelor with aspirin for 1month followed by ticagrelor
monotherapy for 23months. The study failed to show superiority for
the intervention, although a trend towards a reduction in the primary
composite endpoint of death or newQ-wave infarctionwas apparent
[HR 0.87 (0.75–1.01); P=0.073]. Risk of bleeding was almost identical
in the two groups, regardless of DM status.75,76 The more recent ana-
lysis of the subgroup of DM individuals and CKD (higher risk of
thrombosis and bleeding) showed no significant reduction in the pri-
mary endpoint with the intervention, although lower rates of the
patient-oriented composite endpoint (POCE; death, stroke, site-
reported MI/revascularization) were observed in the ticagrelor group
compared with controls [20.6% vs. 25.9%, HR 0.74 (0.55–0.99)] with
similar reduction in net adverse clinical events (POCE plus BARC 3
and 5 bleeding events) [22.7% vs. 28.3%, HR 0.75 (0.56–0.99)].77
Moreover, a recent meta-analysis has shown that, following PCI,
monotherapy with a P2Y12 inhibitor is preferable to DAPT in older
individuals and those with diabetes, CKD or multivessel disease due
to reduction in bleeding risk.78 Therefore, de-escalation of DAPT
may be an option in some patients, particularly when using potent
P2Y12 inhibitors as monotherapy.
79 However, de-escalation is per-
haps best avoided in the DM population, given the high vascular risk,
unless there are major concerns over bleeding risk and this remains
an area for future research.
Glycoprotein IIb/IIIa inhibitors
GP inhibitor (GPI) use in ACS significantly reduced 30-day mortality,
particularly in DM patients undergoing PCI, but this benefit was
observed before routine P2Y12 inhibitor use.
80 Abciximab reduced
MACE in ACS patients undergoing PCI, even with clopidogrel pre-
treatment, but the benefit in DM patients was less pronounced
(abciximab has now been withdrawn in Europe).81 In contemporary
practice using potent P2Y12 inhibitors, GPI therapy is mainly reserved
for ‘bail-out’ in case of no-reflow or a thrombotic complication dur-
ing PCI,82 although some benefit has been suggested also in opiate-
treated patients undergoing emergency PCI.83
Very-low-dose non-VKA oral anticoagulant
In the ATLAS ACS 2-TIMI 51 trial, the addition of very-low-dose
rivaroxaban (2.5mg twice daily) to DAPT (in the form of aspirin and
clopidogrel) in ACS patients, of whom 32% had DM, significantly
reduced MACE compared to placebo but the DM group appeared to
derive less benefit.84 An increase in bleeding events, including intra-
cranial, was documented and therefore this triple therapy (TT) can
only be advocated for individuals at very high vascular risk with






















































































































































relatively low bleeding risk, accepting the challenge that ischaemic
and bleeding risk factors overlap substantially.55 A summary of the
agents used following ACS is given in Figure 2.
Long-term therapy for secondary
prevention
Default practice is DAPT for 1 year post-ACS followed by antiplate-
let monotherapy, usually with aspirin. However, DM patients have
increased long-term risk of recurrent atherothrombotic events and
should be carefully considered for more intensive long-term antith-
rombotic therapy.85
TheCAPRIE trial (n=19 185) showed that clopidogrel for second-
ary prevention (75mg daily) reduced the composite endpoint of is-
chaemic stroke, MI, or vascular death compared with daily 325mg
aspirin [5.32% vs. 5.83% (0.3–16.5); P=0.043], mostly driven by PAD
events, which showed a significant heterogeneity vs. MI and stroke.86
DM patients (n=3866) showed a similar pattern (P=0.36 for inter-
action) but with an amplified absolute risk reduction (15.6% vs.
17.7%; P=0.042), without an increase in bleeding events.87Given the
high aspirin dose used, it is difficult to recommend a routine switch to
clopidogrel for secondary prevention, except in special clinical scen-
arios, such as individuals with PAD (discussed below). The benefit of
12 vs. 30months of DAPT, mostly consisting of aspirin and clopidog-
rel, was tested in the DAPT trial,88 including 9961 individuals who
had not experienced ischaemic or bleeding events at 1 year post-PCI.
Prolonged DAPT significantly reduced the composite of all-cause
mortality, MI, or stroke [4.3% vs. 5.9%, HR 0.71 (0.59–0.85);
P<0.001] but at the expense of increased moderate/severe bleeding
events [2.5% vs. 1.6%, HR 1.61 (1.21–2.16); P=0.001]. However, in
DM patients (n=3391), this strategy did not affect the composite
outcome [6.6% vs. 7.0%, HR 0.92 (0.71–1.20); P=0.55] although the
limitation of subgroup analysis should be acknowledged.89,90
The PEGASUS-TIMI 54 trial evaluated prolonged ticagrelor use in
21 162 patients with a history of MI 1–3 years prior to enrolment.
Patients also needed to have at least one additional risk factor, which
included DM requiring medication.91 Patients were randomized to ei-
ther one of two doses of ticagrelor (90mg twice daily or 60mg twice
daily) or placebo in addition to aspirin. At 3 years, the primary efficacy
endpoint (cardiovascular death, MI, and stroke) was reduced with
ticagrelor 60mg twice daily compared with placebo [7.8% vs. 9.0% in
placebo, HR 0.84 (0.74–0.95); P=0.004]. TIMI major bleeding events
increased [2.30% vs. 1.06% in placebo, HR 2.32 (1.68–3.21);
P<0.001], but no difference was detected in fatal or intracranial
bleeding. Similar data were documented in the DM subgroup
(n=6806, 32% of study population) with a higher absolute risk reduc-
tion in the 60mg twice daily ticagrelor arm compared with placebo
(11.6% vs. 10.0% in DM subgroup and 7.8% vs. 6.7% in non-DM sub-
group). TIMI major bleeding in those with DM was higher in
ticagrelor-treated individuals compared with placebo [2.5% and 1.0%,
HR 2.5 (1.4–4.4); P=0.0004], an increase that was similar to the non-
DM group (2.39%; P=0.89).91
Figure 2 Summary of antiplatelet and anticoagulant therapies in individuals with diabetes and vascular disease. ACS: acute coronary syndrome; AF:
atrial fibrillation; CAD: coronary artery disease; CVD: cerebrovascular disease; DAPT: dual antiplatelet therapy; NOAC: non-vitamin K antagonist
oral anticoagulants; PAD: peripheral artery disease; SR: sinus rhythm. aDiabetes mellitus individuals with >_1 organ damage or >_3 major risk factors,
or any risk factor and >_10-year disease duration without organ damage. bActive bleeding or comorbidities with high bleeding risk. cHistory of intra-
cerebral haemorrhage or ischaemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastro-
intestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy,
extreme old age or frailty, or renal failure requiring dialysis or with estimated glomerular filtration rate <15 mL/min/1.73 m2. dDiffuse multivessel
CAD with at least one of the following: diabetes mellitus requiring medication, recurrent myocardial infarction, PAD, or chronic kidney disease with
estimated glomerular filtration rate 15–59 mL/min/1.73 m2.



















































































































































































































































The COMPASS study in patients with either prior MI or multives-
sel CAD (n=27 395; 38% with DM) showed that rivaroxaban 2.5mg
twice daily added to low-dose aspirin reduced the risk of MACE
compared with aspirin alone [4.1% vs. 5.4%, HR 0.76 (0.66–0.86);
P<0.001],92 making this an option,85,92,93 particularly in DM patients
who showed greater absolute net benefit.94 While the combination
therapy increased bleeding risk, there was still a net clinical benefit.
Vorapaxar was investigated in the TRA 2P-TIMI 50 study, detailed in
Supplementary material online given the limited clinical use of this
agent.95–97
In summary, following ACS, DAPT for 1 year is the current stand-
ard of care. De-escalation of DAPT intensity or duration may be con-
sidered after 3months if bleeding concerns prevail.98 One year post-
ACS, options include switching to aspirin monotherapy or, in high is-
chaemic and low bleeding risk DM patients, continuation of dual
antithrombotic therapy in the form of aspirin and low-dose ticagrelor
(PEGASUS-TIMI 54 study) or aspirin and very-low-dose rivaroxaban
(COMPASS trial).3,51,85 Studies addressing antithrombotic agents for
secondary prevention are summarized in Table 2 and Supplementary
material online, Figure S1.
Antithrombotic therapy in the presence
of atrial fibrillation
Individuals with DM have a 40% greater risk of developing atrial fibril-
lation (AF) compared to those without DM.99,100 Whilst epidemio-
logical data suggest a causal association, the effect of confounders
cannot be excluded (further discussed in Supplementary material
online, S1).101–109
Antithrombotic therapy
Oral anticoagulation (OAC) is recommended for male and female
AF patients with CHA2DS2-VASc score >_2 and >_3, respectively, but
can also be considered in those with lower scores on an individual
basis.51 In those without absolute indication for VKAs (e.g. mechanic-
al valve or moderate/severe mitral stenosis), NOACs are preferred
due to lower rates of severe bleeding and reduced monitoring
requirements.51,110 In studies comparing NOACs with VKA in non-
valvular AF, about a third of individuals had DM and showed similar
RRR to those without DM.111 However, given the increased risk in
DM, therapy with NOACs translated into a greater absolute benefit,
while rates of major bleeding are similar regardless of DM status. If
OAC is contraindicated, percutaneous left atrial appendage closure is
an option in those with or without DM.112
Antithrombotic therapy in patients with atrial fibrillation and acute cor-
onary syndrome
Patients with AF on OAC who develop ACS and/or undergo PCI
generally require combination treatment with OAC and antiplatelet
therapy, with NOACs preferred over VKA.82,85,113 For TT with
OAC and DAPT, clopidogrel is recommended over more potent
P2Y12 inhibitors.
82,85,113
After elective PCI in patients with AF who require OAC, a
switch from TT (DAPT and OAC) to dual therapy (OAC and
single antiplatelet therapy) should be considered in those at low
risk of stent thrombosis or when bleeding risk is high. North
American guidance encourages dual therapy with early aspirin
cessation (i.e. by the time of hospital discharge).114,115 ESC guid-
ance endorses TT for at least 1month if stent thrombosis risk
outweighs bleeding risk, followed by an antiplatelet agent (usual-
ly clopidogrel) and OAC until 12months post-PCI, and there-
after OAC monotherapy, unless long-term dual therapy is
considered due to very high ischaemic risk with low bleeding
risk.82,85,102,113 Similar differences in international guidance exist
for AF patients with ACS treated with stent implant-
ation.55,56,116,117 The above applies to all individuals regardless
of DM status as no specific studies have been conducted in this
group. A summary of the agents used in patients with AF and
ACS is provided in Figure 2.
Peripheral artery disease
PAD is thought to affect 202 million people worldwide118 and these
individuals are at a higher MACE risk,119 with an even higher event
rate with two or more arterial beds affected.119,120
Asymptomatic peripheral artery disease
Two relatively small trials have compared aspirin vs. placebo in
asymptomatic PAD, the POPADAD trial44 specific to DM and the
AAA trial,121 which included 3% (n=88) of DM patients. Neither
showed a difference in MACE in a combined overall cohort of 4626
patients (1256 with DM). While it can be argued these studies were
underpowered, guidelines generally do not support routine antiplate-
let therapy for asymptomatic lower extremity arterial disease and
these individuals are best managed as per primary prevention recom-
mendations described above.
Symptomatic peripheral artery disease
A meta-analysis of 17 000 individuals with symptomatic PAD has
shown that aspirin reduced serious vascular events by 18.2% per year
(P<0.0001), marginally offset by a non-significant increase in haemor-
rhagic stroke.42
Subgroup analysis of 6452 patients with PAD (21% with DM) in
the CAPRIE study showed potentially greater benefit with clopidog-
rel vs. aspirin [3.71% vs. 4.86%; RRR 24% (8.9–36.2); P=0.0028] com-
pared with the overall study population [5.32% vs. 5.83%; RRR 8.7%
(0.3–16.5); P=0.043].86 The EUCLID trial compared ticagrelor and
clopidogrel in 13 885 patients with symptomatic PAD (38.4% with
DM), finding no difference in MACE [10.8% vs. 10.6%, HR 1.02 (0.92–
1.13); P=0.65] or major bleeding over a median follow-up of
30months, regardless of DM status.122
A subgroup analysis of PAD patients in the CHARISMA trial
(n=3096, 36.2% with DM) showed no significant difference in MACE
comparing aspirin and clopidogrel therapy with aspirin and placebo
[7.6% vs. 8.9%, HR 0.85 (0.66–1.08); P=0.18], similar to the overall
trial cohort [6.8% vs. 7.3%, HR 0.93 (0.83–1.05); P=0.22].123 There
was an increase in minor bleeding with DAPT [34.4% vs. 20.8%, odds
ratio 1.99 (1.69–2.34); P<0.001] but no difference in severe/moder-
ate bleeding. The role of vorapaxar in PAD is described in the
Supplementary material online.124
A systematic review and network meta-analysis reported that as-
pirin, ticlopidine, and ticagrelor or clopidogrel used as monotherapy









































































Table 2 Secondary prevention in diabetes
Sample
size














19 185 Prior ischaemic stroke
(within 1 week–
6months), recent


































dogrel 65% or pra-
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21 162 MI 1–3 years earlier Ticagrelor 90mg b.i.d. vs. placebo 32 Composite of CV
death, MI, or
stroke






















26 449 History of MI, ischae-
mic stroke, or PAD
Vorapaxar (2.5mg
daily)






























































38 Composite of CV
death, stroke,
or MI



















Long-term therapy for secondary prevention trials in patients with established cardiovascular disease.
This is a general guide and healthcare professionals should follow local guidelines as appropriate.
Significant differences are highlighted in bold.
b.i.d., twice daily; CAD, coronary artery disease; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; GI, gastrointestinal; HR, hazard ratio; ICH, intracranial haemorrhage; MACE, major adverse cardiovascular or





































































































































































































(or in combination with aspirin) were effective in reducing MACE in
patients with PAD, and that ticlopidine, vorapaxar, and DAPT
increased bleeding risk.125 Clopidogrel had the best balance between
efficacy [MACE RRR 0.72 (0.58–0.91); NNT 80] and safety profile,
making it the preferred agent to use.
There were 7470 patients with PAD in the COMPASS trial, 44%
of whom had DM with a median follow-up of 21months.126 The
combination of rivaroxaban and aspirin reduced MACE and major
adverse limb events vs. aspirin alone to a similar degree in those with
DM [8% vs. 12%, HR 0.69 (0.53–0.91)] or without [5% vs. 7%, HR
0.69 (0.50–0.94)]. This was associated with a lower incidence of
major adverse limb events in the whole group [1% vs. 2%, HR 0.54
(0.35–0.84); P=0.005], including lower incidence of major amputa-
tion [HR 0.30 (0.11–0.80); P=0.011].
Post-revascularization
Limited evidence suggests that DAPT with aspirin and clopidogrel is
beneficial after lower limb revascularization, particularly following
prosthetic bypass.125,127 Similarly, warfarin, with or without aspirin,
may improve graft patency after vein bypass.128,129 The VOYAGER
PAD trial, assessing aspirin plus rivaroxaban vs. aspirin post-lower
limb revascularization, included 6564 individuals (40% had DM) and
combination therapy reduced the composite of acute limb ischaemia,
major amputation, MI, ischaemic stroke, or cardiovascular death [HR
0.85 (0.76–0.96); P=0.009]. A trend towards an increase in TIMI
major bleeding, but not BARC bleeding, was documented with the
combination therapy [HR 1.43 (0.97–2.10); P=0.07].130 Results of
the DM subgroup analysis are awaited. Antithrombotic management
of individuals with DM and PAD is summarized in Table 3 and
Supplementary material online, Figure S1.
Treatment of individuals with
cerebrovascular disease
Due to lack of DM-specific studies, antithrombotic therapy in individ-
uals sustaining a stroke is similar regardless of DM status and there-
fore studies are discussed accordingly.
Following acute events
In acute severe ischaemic stroke, reperfusion is attempted either
through thrombolysis or endovascular thrombectomy, followed by
antiplatelet monotherapy, usually with aspirin, administered 24 h
later.131,132 Ticagrelor monotherapy showed no superiority over as-
pirin133 and, therefore, is only recommended if aspirin is
contraindicated.132
In those with minor events [National Institute of Health Stroke
Scale (NIHSS) score <_3], high-risk transient ischaemic attack (TIA)
(ABCD2 score >_4) or TIA not requiring thrombolysis or invasive
measures, antiplatelet therapy can be immediately started provided
haemorrhagic stroke is excluded. DAPT (aspirin and clopidogrel) is
recommended given findings from the CHANCE and POINT trials
(21% and 28% of the study population had diabetes, respective-
ly),134,135 starting within 24 h of the event for 21days followed by clo-
pidogrel only.132 While severe haemorrhagic events showed no
increase in CHANCE, a doubling was noticed in POINT (Table 4 and
Supplementary material online, Figure S1), although the benefit of
DAPT still outweighed bleeding risk.135 The more recent THALES
trial randomized 11 016 individuals (29% with diabetes), with ischae-
mic stroke or TIA (NIHSS score <_5; 29% with DM) within 24h of
presentation to DAPT with ticagrelor and aspirin or aspirin alone for
30 days. The primary composite outcome of stroke or death at
30 days occurred in 5.5% in the combination group vs. 6.6% in those
on aspirin alone [HR 0.83 (0.71–0.96); P=0.02] but incidence of dis-
ability showed no difference, while DAPT was associated with
increased rate of severe bleeding (0.5% vs. 0.1%; P=0.001).136 There
was no suggestion in any of the studies that the diabetes subgroup
behaved differently and therefore DAPT in DM should be initiated
within 24h following acute minor stroke not requiring thrombolysis
or thrombectomy and continued for 21–30days. Future work is
required to clarify the optimal duration of DAPT after acute minor
stroke, or the benefit of DAPT following reperfusion therapy.132,137
Long-term non-cardioembolic stroke
prevention
The effect of aspirin on secondary prevention in stroke/TIA patients
is well-established, as are the effects of clopidogrel and aspirin/dipyr-
idamole combination.138 The benefits of aspirin (75–150mg daily) ap-
pear to be most pronounced in the first 6–12weeks following the
event, while combination with dipyridamole may offer better longer-
term protection.139 Clopidogrel is as good as aspirin/dipyridamole
combination and is preferred for secondary prevention, particularly
with the frequent headaches with aspirin/dipyridamole combination
leading to discontinuation.140,141
DAPT for long-term use is discouraged as studies showed exces-
sive bleeding without a vascular benefit.142–145
Taken together, for the management of DM individuals, aspirin is
justified 24h after an acute event requiring reperfusion therapy fol-
lowed by a switch to clopidogrel 3months later (or continue aspirin
while adding dipyridamole). In those not receiving reperfusion ther-
apy, DAPT can be immediately started (provided haemorrhagic
stroke is ruled out) and continued for 21days followed by long-term
monotherapy with clopidogrel (or a combination of aspirin/dipyrid-
amole), which applies to individuals with and without diabetes
(Figure 2).139–141
Stroke prevention in association with
non-valvular atrial fibrillation
As discussed above, anticoagulation is recommended for those with
AF and elevated CHA2DS2-VASc score, of which DM is a
component.113,146,147
Potential superior efficacy of NOACs, together with reduced
bleeding events and reduced need for monitoring, offers distinct
advantages over VKAs. An analysis of four large RCTs [RE-LY,
ARISTOTLE, ROCKET-AF, and ENGAGE AF-TIMI 48 (23%, 25%,
40%, and 36% with DM, respectively)],148–151 enrolling over 70 000
patients with non-valvular AF with at least one additional risk factor
for stroke, demonstrated that dabigatran or factor Xa inhibitors
(apixaban, rivaroxaban, edoxaban) are at least as efficacious as war-
farin, and in some cases superior, in preventing stroke, whilst reduc-
ing bleeding risk. Sub-analysis of DM patients in these trials showed
similar anti-thrombotic benefits of NOACs but bleeding risk reduc-
tion appeared to be attenuated.152–154









































































Table 3 Antithrombotic therapy in peripheral vascular disease
Trial Sample size Population Investigation Control % with
diabetes








1276 Type 1 or 2 diabetes melli-



















AAA (2010)121 3350 ABPI <_0.95; free from clin-
ical CV disease






























CAPRIE (1996)86 6452 Symptomatic PAD and
ABPI <_0.85; or symp-
tomatic PAD with previ-
ous amputation or
revascularization
Clopidogrel 75mg Aspirin 325mg 21% Mean
1.9 years




GI bleed 1.99% vs.
2.66%; P< 0.002 (for
the whole group)












Clopidogrel 75mg 38% Median
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Table 3 Continued
Trial Sample size Population Investigation Control % with
diabetes







3787 Symptomatic PAD and
ABPI <0.85 or previous
lower limb
revascularization
Vorapaxar 2.5mg Placebo 36% Median
36months








Acute limb ischaemia 2.3% vs. 3.9%
HR 0.58 (0.39–0.86);
P50.006











Previous lower limb revas-
cularization or amputa-
tion; symptomatic PAD
and ABPI <0.9 or sten-












MACCE 5% vs. 7%
HR 0.72 (0.57–0.90);
P50.005
Major bleeding 3.1% vs.
1.9%
HR 1.61 (1.12–2.31);































16.7% vs. 7.1%; P<0.001
Severe bleeding
2.1% vs. 1.2%; P = NS
Graft occlusion
HR 0.63 (0.42–0.93) and
amputation
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Table 3 Continued
Trial Sample size Population Investigation Control % with
diabetes




















Occlusion 23.2% vs. 24.3%
HR 0.95 (0.82–1.11)
Total bleeding
119 vs. 59 events
Fatal bleeding
16 vs. 12 events
Gastrointestinal bleeding
51 vs. 29 events
Intracranial bleeding
18 vs. 4 events
Fatal intracranial bleeding
events were higher (8
vs. 3 events) in oral
anticoagulants, where-
as bleeding events in














56 Infrainguinal bypass with
autogenous vein and
deemed high risk for
graft occlusion (subopti-
mal venous conduit,
poor arterial runoff or
redo bypass)
Warfarin (target
INR 2–3) þ as-
pirin 325mg






30-day graft patency 97.3% vs. 85.2%; P=0.07 Haematoma
32% vs. 4%; P50.004
GI bleeding
3% vs. 11%; P = NS
Intracranial bleeding
3% vs. 4%; P = NS
30-day amputation
rate
0% vs. 11.1%; P50.04
3-year primary
assisted patency:
77% vs. 56%; P=0.05
3-year secondary
patency



















Summary of antiplatelet and anticoagulant studies in individuals with peripheral vascular disease.
Significant differences are highlighted in bold.
ABPI, ankle brachial pressure index; b.i.d., twice daily; CV, cardiovascular; DAPT, dual antiplatelet therapy; GI, gastrointestinal; HR, hazard ratio; INR, international normalized ratio; MACE, major adverse cardiovascular or cerebrovascular




























Table 4 Antithrombotic therapy in cerebrovascular disease
Antiplatelet randomized trial for secondary prevention in patients with acute minor ischaemic stroke/high-risk TIA
Study Patients Intervention Control Follow-up Composite vascular













































on day 1–5, then
81mg/day afterward)










(N=6589; 24.3% with DM)
Non-severe stroke
(NIHSS <5)/high-risk
TIA, onset <24 h
Ticagrelor 180mg loading




















then 90mg b.i.d. on days
2–30
Aspirin 300–325mg loading




o.d. on days 2–30









Anti-platelet randomized trials for long-term secondary prevention in patients with previous non-cardioembolic ischaemic stroke/TIA









(N=19 185; 20% with DM)
Recent MI, PAD, or
stroke
Clopidogrel 75mg/day Aspirin 325mg/day 1.9 years 5.32% vs. 5.83%
HR 0.91 (0.84–1.00)
Not reported 0.35% vs. 0.49% 1.38% vs. 1.55%
(severe bleeding)
CAPRIE (1996)86 stroke subgroup
(N=6431; 25% with DM)
Recent stroke Clopidogrel 75mg/day Aspirin 325mg/day 7.15% vs. 7.71%
HR 0.91 (0.81–1.06)
5.2% vs. 5.7% Not reported Not reported
ESPRIT (2006)140














0.8% vs. 1.5% 2.5% vs. 3.9%
PRoFESS (2008)141
































Anti-platelet randomized trials for long-term secondary prevention in patients with previous non-cardioembolic ischaemic stroke/TIA










(N=7599; 68% with DM)
Recent stroke/TIA within
3months








1.1% vs. 0.7% 1.9% vs. 0.6%
(P< 0.001)
CHARISMA (2006)142































Greving et al. (2019)144
(N=43 112; 33.3% with DM)
Meta-analysis (6 RCTs) Clopidogrel Aspirin 2.0 years 0.88 (0.78–0.98) 0.91 (0.81–1.02) 0.63 (0.43–0.91) 0.76 (0.63–0.91)
Aspirin/dipyridamole 0.83 (0.74–0.94) 0.86 (0.76–0.97) 0.88 (0.60–1.31) 0.86 (0.71–1.05)
Aspirin/clopidogrel 0.83 (0.71–0.96) 0.83 (0.71–0.97) 1.19 (0.68–2.08) 1.63 (1.29–2.07)
Aspirin/dipyridamole Clopidogrel 0.95 (0.85–1.06) 0.95 (0.87–1.04) 1.40 (1.08–1.82) 1.14 (1.00–1.30)
Aspirin/clopidogrel 0.94 (0.82–1.08) 0.91 (0.80–1.04) 1.88 (1.12–3.16) 2.16 (1.72–2.71)
Aspirin/clopidogrel Aspirin/dipyridamole 0.99 (0.84–1.17) 0.96 (0.82–1.13) 1.34 (0.77–2.36) 1.89 (1.47–2.42)
Anti-coagulant randomized trials for primary and secondary preventions in patients with atrial fibrillation











Apixaban 2.5mg b.i.d. in
age >80 years, body
weight <60 kg, cre-
atinine >1.5mg/mL
Warfarin (keep INR 2.0–
3.0)




























men or >3 for women
Dabigatran 110mg b.i.d. Warfarin (keep INR 2.0–
3.0)



















DM patients were younger,
more CAD and PAD,
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scores















































Anti-coagulant randomized trials for primary and secondary preventions in patients with atrial fibrillation
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tant use of verapamil
or quinidine)
Warfarin (keep INR 2.0–
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<60 kg, or concomi-










Antiplatelet platelet and anticoagulant for secondary prevention in atrial fibrillation patients ineligible for vitamin K antagonist











CHADS2 >1, or docu-
mented PAD
Apixaban 5mg b.i.d.
Apixaban 2.5mg b.i.d. in
age >80 years, body
weight <60 kg, creatin-
ine >1.5mg/mL








Antiplatelet and anticoagulant studies for secondary prevention in individuals with cerebrovascular disease.
Significant differences are highlighted in bold.
b.i.d., twice daily; CAD, coronary artery disease; CHA2DS2-VASc, score, Congestive Heart failure, hypertension, Age >_75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); CHADS2 score, Cardiac fail-
ure, Hypertension, Age, Diabetes, Stroke (doubled); CVD, cardiovascular disease; DM, diabetes mellitus; HAS-BLED score, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile INR,
elderly (65 years), drugs/alcohol concomitantly (1 point each); HR, hazard ratio; MI, myocardial infarction; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; PAD, peripheral artery disease; TIA, transient ischae-




















































































































































































In AF patients who are ineligible for VKA, apixaban (AVERROES
trial; 20% with diabetes) is the only NOAC that has demonstrated su-
perior efficacy to aspirin in preventing MACE (stroke, systemic em-
bolism, MI, and vascular death) with similar bleeding risk in the whole
study population with no subgroup analysis conducted for those with
DM.155
In summary, current evidence supports OAC in DM individuals
with AF with or without a history of stroke who fulfil treatment crite-
ria and do not have excessive bleeding risk. NOACs are preferable
to VKAs in eligible patients.
Timing of initiation (or therapy resumption) of OAC in AF patients
suffering an acute stroke is a challenging area. Based largely on two
studies, RAF and RAF-NOACs,156,157 the American Heart
Association/American Stroke Association 2018/2019 guidelines rec-
ommend starting OAC within 4–14days of an acute ischaemic
stroke.132 The European Heart Rhythm Association-ESC guidelines
give a more structured recommendation with the ‘1–3–6–12 days
rule’.158 In brief, OAC should be initiated or reinstated after 1 day for
TIA, 3 days for mild stroke (NIHSS score <8), 6 days for moderate
stroke (NIHSS score 8–15), and 12days for severe stroke (NIHSS
score >_16). These recommendations are based solely on expert con-
sensus without robust RCTs supporting this approach. Of note,
bridging with full-dose low-molecular-weight heparin before or to-
gether with VKA is not recommended.159 Table 4 summarizes key
studies on antithrombotic agents in cerebrovascular disease.
Conclusions and future directions
While a large number of studies investigated the best antithrombotic
strategy in vascular disease patients, there is still a distinct lack of DM-
specific RCTs, particularly for secondary prevention. The heteroge-
neous vascular risk in DM patients, which can vary in the same indi-
vidual according to DM duration and development of complications,
adds to the complexity and prevents guidelines from making con-
crete recommendations. For example, advanced renal disease may
alter both thrombosis and bleeding risk and may even limit the use of
some antithrombotic therapies.33 The increased weight in DM indi-
viduals may also affect the response to antithrombotic agents,
reviewed elsewhere.160 A key difficulty remains the lack of bio-
marker(s) that accurately predicts thrombotic/bleeding risk and re-
sponse to therapy.
Given current knowledge, primary prevention with antiplatelet
agents, mainly aspirin, may only be considered in higher-risk individu-
als. Following ACS, DAPT is necessary using aspirin and ticagrelor or
prasugrel, usually for 12months but also longer term with aspirin and
ticagrelor in high thrombotic risk patients. In stable atherosclerotic
disease, the combination of aspirin and very-low-dose rivaroxaban is
useful, particularly in the presence of PAD (Figure 2).161 In individuals
with stroke, the choice of antithrombotic therapy is dictated by
whether the individual required reperfusion and the presence of AF
(Figure 2 and Graphical Abstract).
Areas for future research include the development of reliable bio-
markers and/or in silico model, able to assess thrombotic risk and re-
sponse to therapy. Moreover, DM-specific studies are warranted
rather than subgroup, and often post hoc, analyses of cardiovascular
trials designed for the wider population (DM-specific studies are
summarized in Supplementary material online, Table S3 and gaps in
knowledge/future work in Supplementary material online, Table S4).
This will require greater collaboration between metabolic and vascu-
lar medical disciplines to design appropriate studies aiming to reduce
vascular events and improve clinical outcomes in the high-risk DM
population.
Supplementary material
Supplementary material is available at European Heart Journal online.
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